EP0000741B1 - Indolacetoxyacetylaminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel - Google Patents

Indolacetoxyacetylaminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel Download PDF

Info

Publication number
EP0000741B1
EP0000741B1 EP78100523A EP78100523A EP0000741B1 EP 0000741 B1 EP0000741 B1 EP 0000741B1 EP 78100523 A EP78100523 A EP 78100523A EP 78100523 A EP78100523 A EP 78100523A EP 0000741 B1 EP0000741 B1 EP 0000741B1
Authority
EP
European Patent Office
Prior art keywords
ace
carbon atoms
general formula
group
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP78100523A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0000741A3 (en
EP0000741A2 (de
Inventor
Karl-Heinz Dr. Boltze
Hans-Dieter Dr. Dell
Haireddin Dr. Jacobi
Wolfgang Dr. Opitz
Günter Schöllnhammer
Dieter Dr. Vollbrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Troponwerke GmbH
Original Assignee
Troponwerke GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Troponwerke GmbH filed Critical Troponwerke GmbH
Publication of EP0000741A2 publication Critical patent/EP0000741A2/de
Publication of EP0000741A3 publication Critical patent/EP0000741A3/xx
Application granted granted Critical
Publication of EP0000741B1 publication Critical patent/EP0000741B1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Definitions

  • the present invention relates to new indolacetoxyacetylamino acid derivatives, processes for their preparation and their use in medicaments, in particular in anti-inflammatories and anti-inflammatory drugs.
  • physiologically compatible addition salts can be formed with organic and inorganic bases.
  • salts are preferably sodium salts, potassium, magnesium, ammonium, methylammonium, dimethylammonium salts or the 2-hydroxy, ethyl ammonium salt.
  • addition salts which are physiologically compatible can also be formed with acids.
  • salts are halides, preferably chlorides, sulfates, citrates, tartrates, maleinates and sulfonates.
  • the compounds of general formula (I) according to the invention have a more advantageous activity than the indomethacinserine derivatives of DOS 2 413 125 known from the prior art, as can be seen from the following table.
  • the active substances were administered orally to rats half an hour before the kaolin application (dose: see columns 2 and 4).
  • dose see columns 2 and 4
  • the inhibition was determined 4 hours after the edema challenge to control groups (see columns 3 and 5).
  • the serine derivative according to the invention was compared with the known serine derivative of indomethacin by determining DE 50 in each case. This shows that the serine derivative according to the invention has a DE 50 of 2.14 mg / kg body weight in rats after oral administration and a DE 50 of 2.17 mg / kg body weight in subcutaneous administration. The corresponding DE so values of the serine derivative of indomethacin were in any case over 100 mg / kg body weight.
  • reaction sequence of variant a) can be represented by the following formula:
  • chloroformic acid esters of the general formula (11) which can be used as starting compounds are known and the ACE-OH used as starting compound is also known (DOS 2 234 651).
  • the mixed anhydrides of the general formula (111) formed as an intermediate are new, but cannot be identified, since - like the majority of the mixed anhydrides known in the literature - they decompose during processing (cf.Houben-Weyl, Methods of Organic Chemistry, 4th edition, volume 15/2, page 17, 3rd paragraph).
  • diluents inert organic solvents are suitable as diluents, in particular those which are polar aprotic. Examples include: tetrahydrofuran, dioxane, dimethylformamide, hexamethylphosphoric triamide.
  • the reaction is conveniently carried out in the presence of acid binders.
  • acid binders All customary agents which are able to bind the hydrogen chloride released can be used as the acid binder. These preferably include alkali metal hydroxides and carbonates or organic bases such as pyridine and triethylamine.
  • reaction temperatures are expediently below 0 ° C., since otherwise racemizations occur; they can be varied within a certain range.
  • temperatures between 0 to -25 ° C, preferably between -10 and -20 ° C.
  • the reaction is usually carried out at normal pressure.
  • the reaction time is between 6 and 24 hours, preferably 14 to 20 hours.
  • Working up is preferably carried out by evaporation in vacuo, taking up in one of the customary organic solvents, neutral washing, optionally cleaning on silica gel and recrystallization.
  • reaction scheme If an activated ester of the general formula (V) is used for the reaction instead of a mixed anhydride of ACE-OH, the reaction of variant b) can be represented by the following reaction scheme:
  • the compounds of the general formula (V) used as reactants are not yet known, but can be prepared in a manner known per se by reacting 1 mol of ACE-OH and 1 mol of the correspondingly substituted phenol in a polar aprotic organic solvent, e.g. Tetrahydrofuran, in the presence of 1 mole of a carbodiimide, e.g. Dicyclohexylcarbodiimide or carbonyldiimidazole can be obtained in about 1 1/2 hour reaction time at room temperature.
  • a polar aprotic organic solvent e.g. Tetrahydrofuran
  • Process (V) (I) according to the invention is advantageously carried out in the presence of diluents.
  • diluents are the organic solvents known for this reaction, preferably dimethylformamide, dioxane, pyridine or their mixtures with water.
  • addition salts of (IV) are used for reactions, the process is advantageously carried out in the presence of acid binders.
  • acid binders include: alkali metal hydroxides, carbonates or strong organic amines, preferably triethylamine.
  • the reaction temperatures can be varied within a certain range. Normally one works at 15 to 25 ° C, since the reaction times are disproportionately longer at lower temperatures, but the formation of racemates is promoted at higher temperatures. A certain racemate formation cannot be ruled out even in the reaction at room temperature.
  • the process is usually carried out at normal pressure.
  • 1 mol of the amino acid derivative (IV) is preferably used per mole of the activated ester (V).
  • Working up is expediently carried out by diluting the mixture with water, taking it up in a suitable organic solvent, neutralizing, evaporating and recrystallizing from suitable solvents.
  • the serine derivatives of the general formula (VI) used as starting compounds are known.
  • the reaction is preferably carried out in the presence of diluents.
  • Polar aprotic organic solvents can be used as diluents. Examples include tetrahydrofuran, dioxane, dimethylformamide, hexamethylphosphoric triamide.
  • the reaction according to the invention is preferably carried out in the presence of a dehydrating agent.
  • a dehydrating agent examples include dicyclohexylcarbodiimide or carbonyldiimidazole in the presence of catalytic amounts of a basic catalyst, preferably sodium hydride.
  • reaction temperatures can be varied over a wide range; Usually one works between 10 and 40 ° C, preferably between 15 and 25 ° C.
  • ACE-OH 1 mol of the ACE-OH is first reacted with 1 mol of carbonyldiimidazole and 1 mol of the amino acid derivative is only added after CO 2 evolution has ended.
  • Working up is carried out in a conventional manner, preferably by evaporation in vacuo, taking up in a suitable solvent and cleaning on silica gel.
  • the amino protective group R 6 is cleaved off according to the methods known from the literature in peptide chemistry.
  • the new active ingredients can be converted in a known manner into the customary formulations, such as tablets, capsules, dragées, pills, granules, aerosols, syrups, emulsions, suspensions, solutions, ointments, gels, creams, jellies, using inert, non-toxic, pharmaceutically suitable Carriers or solvents.
  • the therapeutically active compound should be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. in amounts sufficient to achieve the dosage range indicated.
  • the formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, e.g. if water is used as the diluent, organic solvents can optionally be used as auxiliary solvents.
  • the application takes place in the usual way, preferably orally or parenterally, locally, intramuscularly or intravenously.
  • tablets in addition to the carrier substances mentioned, can also contain additives such as sodium citrate, calcium carbonate and dicalcium phosphate, together with various additives such as starch, preferably potato starch, gelatin and the like.
  • Lubricants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting.
  • the active ingredients can be mixed with various flavor enhancers or colorants in addition to the auxiliaries mentioned.
  • solutions of the active ingredients can be used using suitable liquid carrier materials.
  • the dosage is about 10 up to 200, especially 30 to 80 mg per dose.
  • the compound is formed in a known manner by adding trifluoroacetic acid to the compound from Example 15.
  • Example 15 analogous to Example 15 from 10.15 g ACE-OH and 5.7 g Boc-Serinethylester.
  • a suspension of 0.005 mol of phenylalanyl tyrosine methyl ester trifluoroacetate in 15 ml of absolute dimethylformamide is initially mixed with stirring at 0 ° C. with 0.005 mol of triethylamine and after 10 minutes with 0.005 mol of ACE-2,4,5-trichlorophenyl ester. After stirring for 2 hours, lastly at room temperature, 150 ml of water are added to the reaction mixture, the mixture is extracted three times with ethyl acetate and the organic phase is extracted three times with nHCl solution. The solution is then washed neutral with water, dried over Na 2 S0 4 and evaporated. After recrystallization from acetone / petroleum ether, 84% of theory of N-ACE-phenylalanyl tyrosine methyl ester of mp 131 to 132 ° C. is obtained.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP78100523A 1977-08-06 1978-07-27 Indolacetoxyacetylaminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel Expired EP0000741B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19772735537 DE2735537A1 (de) 1977-08-06 1977-08-06 Indolacetoxyacetylaminosaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2735537 1977-08-06

Publications (3)

Publication Number Publication Date
EP0000741A2 EP0000741A2 (de) 1979-02-21
EP0000741A3 EP0000741A3 (en) 1979-03-07
EP0000741B1 true EP0000741B1 (de) 1981-07-22

Family

ID=6015810

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78100523A Expired EP0000741B1 (de) 1977-08-06 1978-07-27 Indolacetoxyacetylaminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel

Country Status (4)

Country Link
EP (1) EP0000741B1 (it)
JP (1) JPS5430160A (it)
DE (2) DE2735537A1 (it)
IT (1) IT7826537A0 (it)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3034005C2 (de) * 1980-09-10 1982-12-09 A. Nattermann & Cie GmbH, 5000 Köln Indolessigsäure-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
DE3206885A1 (de) * 1982-02-26 1983-09-15 Troponwerke GmbH & Co KG, 5000 Köln Indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3206887A1 (de) * 1982-02-26 1983-09-15 Troponwerke GmbH & Co KG, 5000 Köln Verfahren zur herstellung von 1-(4-chlorbenzoyl)-5-methoxy-2-methyl-3-indolacetoxyessigsaeure
JPS59204172A (ja) * 1983-04-28 1984-11-19 Kowa Co アセメタシンの製造法
JPH0417306Y2 (it) * 1984-12-26 1992-04-17
ATE115564T1 (de) * 1988-07-05 1994-12-15 Zeria Pharm Co Ltd Indolessigsäure-derivate, verfahren zur herstellung sowie arzneimittel, die diese als aktive mittel enthalten.
US6762182B1 (en) 1999-01-07 2004-07-13 Vanderbilt University Converting cox inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors
US6207700B1 (en) 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
US6306890B1 (en) 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
CN101031289A (zh) 2004-04-26 2007-09-05 范德比尔特大学 作为具有降低胃肠毒性的治疗剂的吲哚乙酸和茚乙酸衍生物
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
CA2657691A1 (en) 2006-06-19 2007-12-27 Vanderbilt University Methods and compositions for diagnostic and therapeutic targeting of cox-2
EP3078374B1 (en) 2011-10-17 2019-06-19 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2234651C3 (de) * 1972-07-14 1978-11-09 Troponwerke Gmbh & Co Kg, 5000 Koeln Eckige Klammer auf l-(p-Chlorbenzoyl)-5-methoxy-2-methyl-3-indol] -acetoxj essigsaure, ihre Salze mit Basen, Verfahren zu ihrer Herstellung sowie pharmakologische Zubereitungen
DE2413125C2 (de) * 1974-03-15 1983-06-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen Indolylacetylaminosäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneipräparate

Also Published As

Publication number Publication date
EP0000741A3 (en) 1979-03-07
IT7826537A0 (it) 1978-08-04
DE2860858D1 (en) 1981-10-29
JPS5430160A (en) 1979-03-06
DE2735537A1 (de) 1979-02-22
EP0000741A2 (de) 1979-02-21

Similar Documents

Publication Publication Date Title
DE2366070C2 (it)
EP0104342B1 (de) Triphenylimidazolyloxyalkansäuren und ihre Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
EP0000741B1 (de) Indolacetoxyacetylaminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel
EP0242851A1 (de) N-(2'-Aminophenyl)-benzamid-Derivate, Verfahren zu deren Herstellung und deren Verwendung bei der Bekämpfung neoplastischer Erkrankungen
EP0089637A2 (de) Neue Derivate bicyclischer Aminosäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung sowie neue bicyclische Aminosäuren als Zwischenstufen und Verfahren zu deren Herstellung
EP0115039B1 (de) Substituierte Phenylsulfonyloxybenzimidazolcarbaminate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE2901170C2 (it)
DE3232672A1 (de) (omega)-(4-(pyrid-2'-yl)-piperazin-1-yl)-alkylcarbonylanilide, verfahren und zwischenprodukte zu ihrer herstellung und die ersteren enthaltende arzneimittel
EP0116360A1 (de) 1-Phenyl-2-aminocarbonylindol-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2727670A1 (de) Neue dipeptide, verfahren zur ihrer herstellung und pharmazeutische praeparate enthaltende solche dipeptide
EP0148431A1 (de) Neue Benzimidazole, ihre Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0018360B1 (de) N-(5-Methoxybentofuran-2-ylcarbonyl)-N'-benzylpiperazin und Verfahren zu dessen Herstellung
DE1023039B (de) Verfahren zur Herstellung von 5-Piperazino-pyridazon-(6)-verbindungen
EP0665228A1 (de) Neue 3-Phenylsulfonyl-3,7-diazabicyclo(3,3,1)nonan-Verbindungen enthaltende Arzneimittel
EP0271099A2 (de) Substituierte Aminopropionsäureamide, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung sowie die bei der Herstellung anfallenden neuen Zwischenprodukte
EP0044266B1 (de) Neue substituierte 3,5-Diamino-1,2,4-oxadiazole und 3,5-Diamino-1,2,4-thiadiazole, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
EP0083729B1 (de) Substituierte 1-Benzoyl-2-phenylimino-imidazolidine, deren Säureadditionssalze, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
EP0124479B1 (de) Iminosulfonamide und Verfahren zu ihrer Herstellung, die pharmazeutische Präparate solche Verbindungen enthalten, sowie die Verbindungen zur Verwendung
DE3426720A1 (de) Benzthiazepinon- und benzthiazocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung
DE1445873A1 (de) Verfahren zur Herstellung von Benzodiazepin-Derivaten
DE3704404A1 (de) Abietamidderivate
DE2608238A1 (de) Substituierte phenylguanidine und verfahren zu ihrer herstellung
DE2200648A1 (de) Verfahren zur Herstellung von monosubstituierten 1-Carbamoyl-2-benzimidazolyl-carbamaten
EP0371342A1 (de) 2-Halogensubstituierte N-Indolylethyl-sulfonsäureamide, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
DE1933388C (de) l-(2-Acyl- 1,2,3,4-tetrahydroisochinolin-7sulfonyl)-harnstoffe

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

17P Request for examination filed
AK Designated contracting states

Designated state(s): BE CH DE FR GB NL

17P Request for examination filed
AK Designated contracting states

Designated state(s): BE CH DE FR GB NL

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19810630

Year of fee payment: 4

AK Designated contracting states

Designated state(s): BE CH DE FR GB NL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19810731

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19810930

Year of fee payment: 4

Ref country code: CH

Payment date: 19810930

Year of fee payment: 4

Ref country code: BE

Payment date: 19810930

Year of fee payment: 4

REF Corresponds to:

Ref document number: 2860858

Country of ref document: DE

Date of ref document: 19811029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19820731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19830127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19830201

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19830331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19830401

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881117

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT